Legacy Pharmaceutical Packaging, LLC
Legacy Pharmaceutical Packaging, LLC (United States) has no DMF, CEP or site registration linked in our records. 50 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Legacy Pharmaceutical Packaging, LLC: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/legacy-pharmaceutical-packaging-llc
Overview
Legacy Pharmaceutical Packaging, LLC is a private company that specializes in contract packaging for the pharmaceutical industry. They provide services such as bottling, blister packaging, compliance packaging, and other related services. The company is known for its commitment to quality and compliance with industry standards.
Therapeutic areas
FDA compliance signals
50 FDA enforcement records linked to this company.
- recall — Class II2024-01-03
CGMP Deviations: Inadequate line clearance which may result in a potential comingling of product.
- 4832023-06-30
SOPs not followed / documented
- 4832023-06-30
Packaging line inspection before use
- 4832023-06-30
Investigations of discrepancies, failures
- 4832023-06-30
Training , Education , Experience overall
- 4832023-06-30
Written procedures not established/followed
- 4832023-06-30
Calibration/Inspection/Checking not done
- warning_letter2022-10-03
FDA Warning Letter (drug product)
- recall — Class III2020-10-07
Presence of Foreign Tablets/Capsules: Metformin 1000mg with different imprint was found in bottles.
- recall — Class II2019-05-08
CGMP Deviations: Detection of trace amounts of N-Methylnitrosobutyric acid (NMBA) impurity found in the Active Pharmaceutical Ingredient (API)
- recall — Class II2019-04-10
CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected.
- recall — Class II2019-03-27
CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected
- recall — Class II2019-03-27
CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected
- recall — Class II2019-03-27
CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected
- 4832017-05-26
Records reviewed annually
- 4832017-05-26
Procedure Deviations Recorded and Justified
- 4832017-05-26
Lack of written stability program
- recall — Class II2017-03-29
Presence of Foreign Tablets/Capsules: Customer complaint that a bottle of atenolol 50 mg Tablets USP contained a paroxetine 20 mg tablet.
- 4832015-07-09
Calibration/Inspection/Checking not done
- 4832015-07-09
SOPs not followed / documented
- 4832015-07-09
Reprocessing procedures not written or followed
- 4832015-07-09
In-process materials specifications
- 4832015-07-09
Chronological Order of Equipment Log Entries
- 4832015-07-09
Specific information required in individual logs
- 4832015-07-09
Written record of investigation incomplete
- 4832014-08-29
Absence of Written Procedures
- 4832014-08-29
Procedures not in writing, fully followed
- 4832014-08-29
Changes to Procedures Not Reviewed, Approved
- 4832014-08-29
SOPs not followed / documented
- 4832014-08-29
Approve or reject procedures or specs
- 4832014-08-29
Extent of discrepancy, failure investigations
- recall — Class II2014-06-18
Correct Labeled Product Miscart/Mispack: some cartons labeled as Pantoprazole Sodium Delayed-Release may contain correctly labeled blister cards of Lorazepam tablets
- recall — Class II2014-05-07
Chemical Contamination: The recalling firm received notice that their supplier is recalling capsules due to complaints of capsules having an unusual odor.
- 4832013-11-26
No written record of investigation
- 4832013-11-26
Training--operations, GMPs, written procedures
- 4832013-11-26
Written warehousing procedures established/followed
- 4832013-11-26
Procedures not in writing, fully followed
- 4832013-11-26
Sampling/testing of labeling/packaging materials
- 4832013-11-26
SOPs not followed / documented
- 4832013-06-18
Quarantine Storage of Components
- 4832013-06-18
Quarantine - actual practice
- 4832013-06-18
Training , Education , Experience overall
- 4832013-06-18
Quarantine of Rejected Components et. al.
- 4832013-06-18
Deviations from laboratory control requirements
- 4832013-06-18
SOPs not followed / documented
- 4832013-06-18
Procedures To Be in Writing
- recall — Class III2013-06-12
Labeling: Incorrect or Missing Lot and/or Exp Date: Lorazepam Lot # L-04009
- recall — Class II2013-05-22
Labeling: Label Error on Declared Strength-The recalled product has a misprint on the Amoldipine 10 mg label, 5 mg is listed in the USP description. Tablet strength is 10 mg.
- 4832011-12-20
Documentation of Sampling Performed
- 4832010-04-26
Procedures to be written and followed
Is this Legacy Pharmaceutical Packaging, LLC?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.